TY - JOUR
T1 - Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
T2 - Journal of Clinical Oncology
AU - Botta, Gregory P.
AU - Abdelrahim, Maen
AU - Aushev, Vasily N.
AU - Esmail, Abdullah
AU - Drummond, Bridgette
AU - Sharma, Shruti
AU - Kalashnikova, Ekaterina
AU - Hook, Nicole
AU - Chandana, Sreenivasa R
AU - Tejani, Mohamedtaki Abdulaziz
AU - Malla, Midhun
AU - Schafer, Liudmila N.
AU - Kasi, Pashtoon Murtaza
AU - George, Giby V.
AU - Aleshin, Alexey
AU - Dayyani, Farshid
AU - Hanna, Diana L.
N1 - doi: 10.1200/JCO.2022.40.4_suppl.517
PY - 2022
Y1 - 2022
N2 - 517Background: Pancreatic adenocarcinoma (PDAC) is the third leading cause of cancer-related death, with a recurrence rate of 85% after curative surgery and a 5-year survival rate of 10%. Serum biomarkers like CA 19-9 lack sensitivity and specificity (10% of patients fail to produce CA 19-9), and are poor indicators of molecular residual disease (MRD). Circulating tumor DNA (ctDNA) detection allows for MRD identification months ahead of radiological findings, and may assess molecular response and patient outcomes. Methods: A personalized and tumor-informed multiplex PCR assay (Signatera? bespoke mPCR NGS assay) was used for the detection and quantification of ctDNA in a prospective clinical cohort of patients. Serial time points were collected for unresectable, borderline resectable, and resectable subsets of patients to monitor ctDNA levels in response to treatment (see Table). Results: 93 patients were included, with a median age of 67.3 yrs and 45% female. 285 timepoints were analyzed for ctDNA presence, with each patient having between 1 and 7 timepoints (median 3 timepoints per patient). 46 patients had one or more samples positive for ctDNA, resulting in an anytime ctDNA positivity rate of 49.5%. Anytime positivity correlated with the stage of disease (p
AB - 517Background: Pancreatic adenocarcinoma (PDAC) is the third leading cause of cancer-related death, with a recurrence rate of 85% after curative surgery and a 5-year survival rate of 10%. Serum biomarkers like CA 19-9 lack sensitivity and specificity (10% of patients fail to produce CA 19-9), and are poor indicators of molecular residual disease (MRD). Circulating tumor DNA (ctDNA) detection allows for MRD identification months ahead of radiological findings, and may assess molecular response and patient outcomes. Methods: A personalized and tumor-informed multiplex PCR assay (Signatera? bespoke mPCR NGS assay) was used for the detection and quantification of ctDNA in a prospective clinical cohort of patients. Serial time points were collected for unresectable, borderline resectable, and resectable subsets of patients to monitor ctDNA levels in response to treatment (see Table). Results: 93 patients were included, with a median age of 67.3 yrs and 45% female. 285 timepoints were analyzed for ctDNA presence, with each patient having between 1 and 7 timepoints (median 3 timepoints per patient). 46 patients had one or more samples positive for ctDNA, resulting in an anytime ctDNA positivity rate of 49.5%. Anytime positivity correlated with the stage of disease (p
U2 - 10.1200/JCO.2022.40.4_suppl.517
DO - 10.1200/JCO.2022.40.4_suppl.517
M3 - Article
SN - 0732-183X
VL - 40
SP - 517
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 4_suppl
ER -